Iambic Therapeutics Secured $150 Mn in IPO to Advance Cancer Drug Candidates

Iambic priced its shares at $16 each, raising the midpoint of its marketed price range. Its shares began trading on the Nasdaq Global Select Market on October 15, 2026, under the ticker symbol IAM.

Iambic Therapeutics' IPO and Valuation

At the IPO price of $16 per share, Iambic was valued at approximately $758 million. This was below the maximum valuation of $806 million that the company had targeted during its IPO marketing.

The company had previously planned to raise $135 million through the offering. The final IPO raised $150 million.

The offering was led by JPMorgan Chase, Jefferies Financial Group, Bank of America and Citigroup.

How Iambic Will Use the Funding

Iambic plans to use the IPO proceeds to advance three early-stage cancer drug candidates. Its drug discovery platform combines AI, machine learning and computational methods to support the development of new treatments.

The company is working to use AI to accelerate drug discovery and improve the process of identifying potential treatments. Its focus on oncology comes as investors increasingly look at the potential applications of AI in healthcare and biotechnology.

About Iambic Therapeutics

Iambic Therapeutics is a San Diego-based biotechnology company founded in 2019. The company develops AI and machine learning technologies to support drug discovery and the development of new medicines.

Its work focuses on applying computational methods to identify potential drug candidates across disease areas, including cancer. Through its technology platform and pharmaceutical industry partnerships, Iambic aims to accelerate the drug discovery process and advance new treatments toward clinical development.

Read Also - Hong Kong Launches Embodied AI Hub to Test Robots in Real-World Environments